# A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease

> **NCT03520998** · PHASE2 · COMPLETED · sponsor: **Alkahest, Inc.** · enrollment: 47 (actual)

## Conditions studied

- Alzheimer Disease
- Mild to Moderate Alzheimer Disease

## Interventions

- **DRUG:** GRF6019

## Key facts

- **NCT ID:** NCT03520998
- **Lead sponsor:** Alkahest, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-16
- **Primary completion:** 2019-05-24
- **Final completion:** 2019-05-24
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2021-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03520998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03520998, "A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT03520998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*